Photrexa cross-linking kit 6ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWD9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,901
Award facts
- Contract value 100% obligated
- $16,900.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $16,900.92 to DMS Pharmaceutical Group Inc. for the supply of Photrexa Cross-Linking Kit 6ML, a specialized pharmaceutical product. The contract was awarded on November 25, 2025, with an ultimate completion date of December 17, 2025, under firm fixed-price terms. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The order will be fulfilled from the vendor's location in Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025. The parent contract carries a $500 million ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting Department of Defense healthcare operations globally. The PPV-G GEN V program represents a $30.3 billion strategic acquisition framework designed to streamline pharmaceutical procurement and supply chain management for military healthcare facilities worldwide, with DMS Pharmaceutical Group demonstrating substantial performance capability across diverse product categories including oncology treatments, biologics, vaccines, specialty pharmaceuticals, and medical consumables.
Quick answers
Who was awarded contract SPE2DR26FQWD9?
SPE2DR26FQWD9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 25, 2025.
How much is contract SPE2DR26FQWD9 worth?
The government has obligated $16,901 on SPE2DR26FQWD9.
Is contract SPE2DR26FQWD9 an order under another contract?
Yes. SPE2DR26FQWD9 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWD9 competed?
The extent of competition for SPE2DR26FQWD9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award